Full-Time

Quality Associate

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$85k - $105k/yr

San Diego, CA, USA

In Person

Must be onsite in San Diego; 10-20% travel domestically and internationally.

Category
Biology & Biotech (1)
Required Skills
Veeva
Requirements
  • Minimum of 2-3 years of experience in QA batch record review and leading QA oversight of Contract Manufacturing Organizations (CMOs)
Responsibilities
  • Support Quality Assurance Batch Record Review, Product Disposition, and QA Supplier Management including associated quality record management for small molecule, biologics, and device products
  • Perform QA Batch Review and Approval of intermediates, drug substance, and final products ensuring all required quality records are complete and compliant prior to product disposition to meet clinical and commercial production timelines
  • Collaborate closely with Technical Operations and Clinical Operations Personnel responsible for Manufacturing, Labeling, Packaging, Batch Kitting, and Distribution
  • Support QA Supplier Management and Oversight of Contract Manufacturing Organizations (CMOs) starting with Phase 2 Clinical Trials through marketed products, and in all situations where GMP Batches are required
  • Manage assigned SOPs revisions and quality records (CAPAs, Deviations, Investigations, Product Complaints, Audit Responses, Change Controls, & Trainings) to ensure timely completion for the organization and associated department(s)
  • Participates in supplier meetings, managing production timelines with batch release activities
  • Support products for clinical development and commercial production including Oral Drugs, Biologics, and Combination Products
  • Provides daily oversight of quality systems records including, CAPAs, Deviations, Investigations, Batch Record Review, and Change Controls
  • Support revision of the existing SOP(s) and Work Instructions related to assigned duties to help define a clear and accurate process
  • Support audit program activities for internal, external, mock, and regulatory audits
  • Provide quality and compliance oversight and act as a SME for the Quality Systems at Travere including, but not limited to: Veeva Quality Vault (QualityDocs and QMS), Document Management, Quality Events (Complaints, Deviations, Audit Findings, Change Controls), Quality Actions (Audits, CAPAs, Effectiveness Checks, Investigations, Root Causes), Quality Metrics
  • Ensure documentation in support of regulatory submissions is uploaded in QualityDocs appropriately
  • Oversee the creation, revision, review, and approval of GxP controlled documents (e.g., SOPs, WINs, Forms) and records
  • Additional duties assigned as needed
Desired Qualifications
  • Broad knowledge of current Good Manufacturing Practices (Code of Federal Regulations / International Council for Harmonisation) and applicable international regulations and guidelines
  • Preference for candidates familiar and experienced with electronic document management systems and Quality Management Systems such as Veeva or similar
  • Strong professional experience in a similar role within the pharmaceutical industry, providing supplier management support for pharmaceutical, medical device, or combination products
  • Prior line management experience with ability to effectively manage performance, engage team members, provide coaching, implement improvements, and respond to situations affecting staff
  • Experience with regulatory inspections

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Your Connections

People at Travere Therapeutics who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FSGS approval unlocks 30,000-patient market, driving near-term revenue growth.
  • FILSPARI sales hit $105.2M in Q1, up 88% year-over-year with strong uptake.
  • BTK inhibitor deal adds $1.14B potential value, broadening immune-mediated indications.

What critics are saying

  • FILSPARI safety label limits prescribing, including pregnancy and hepatotoxicity risks.
  • Revenue concentrated in FILSPARI, making launch execution and reimbursement critical failures.
  • R&D leadership transition in 2027 concentrates execution risk on one leader.

What makes Travere Therapeutics unique

  • Unique focus on rare kidney and metabolic disorders with dual-therapy franchise.
  • First approved FSGS treatment via FILSPARI, expanding beyond IgA nephropathy.
  • Novel BTK inhibitor acquisition diversifies pipeline into immune-mediated kidney disease.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.